Denmark · Delayed Price · Currency is DKK Novozymes Statistics
Total Valuation
Novozymes has a market cap or net worth of DKK 188.85 billion. The enterprise value is 211.18 billion.
| Market Cap | 188.85B |
| Enterprise Value | 211.18B |
Important Dates
The last earnings date was Thursday, August 21, 2025.
| Earnings Date | Aug 21, 2025 |
| Ex-Dividend Date | Aug 21, 2025 |
Share Statistics
Novozymes has 465.60 million shares outstanding. The number of shares has decreased by -22.70% in one year.
| Current Share Class | 411.85M |
| Shares Outstanding | 465.60M |
| Shares Change (YoY) | -22.70% |
| Shares Change (QoQ) | +0.77% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 30.96% |
| Float | 346.32M |
Valuation Ratios
The trailing PE ratio is 27.31 and the forward PE ratio is 26.63. Novozymes's PEG ratio is 2.25.
| PE Ratio | 27.31 |
| Forward PE | 26.63 |
| PS Ratio | 6.18 |
| PB Ratio | 2.36 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 42.39 |
| P/OCF Ratio | 27.57 |
| PEG Ratio | 2.25 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.51, with an EV/FCF ratio of 47.40.
| EV / Earnings | 50.13 |
| EV / Sales | 6.91 |
| EV / EBITDA | 20.51 |
| EV / EBIT | 25.52 |
| EV / FCF | 47.40 |
Financial Position
The company has a current ratio of 1.75, with a Debt / Equity ratio of 0.31.
| Current Ratio | 1.75 |
| Quick Ratio | 1.04 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | 2.40 |
| Debt / FCF | 5.56 |
| Interest Coverage | 15.48 |
Financial Efficiency
Return on equity (ROE) is 5.19% and return on invested capital (ROIC) is 5.15%.
| Return on Equity (ROE) | 5.19% |
| Return on Assets (ROA) | 4.40% |
| Return on Invested Capital (ROIC) | 5.15% |
| Return on Capital Employed (ROCE) | 7.32% |
| Revenue Per Employee | 2.89M |
| Profits Per Employee | 398,083 |
| Employee Count | 10,582 |
| Asset Turnover | 0.26 |
| Inventory Turnover | 2.33 |
Taxes
In the past 12 months, Novozymes has paid 1.35 billion in taxes.
| Income Tax | 1.35B |
| Effective Tax Rate | 24.33% |
Stock Price Statistics
The stock price has decreased by -12.23% in the last 52 weeks. The beta is 0.55, so Novozymes's price volatility has been lower than the market average.
| Beta (5Y) | 0.55 |
| 52-Week Price Change | -12.23% |
| 50-Day Moving Average | 435.19 |
| 200-Day Moving Average | 423.94 |
| Relative Strength Index (RSI) | 41.40 |
| Average Volume (20 Days) | 618,341 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Novozymes had revenue of DKK 30.57 billion and earned 4.21 billion in profits. Earnings per share was 14.85.
| Revenue | 30.57B |
| Gross Profit | 17.64B |
| Operating Income | 8.32B |
| Pretax Income | 5.57B |
| Net Income | 4.21B |
| EBITDA | 10.34B |
| EBIT | 8.32B |
| Earnings Per Share (EPS) | 14.85 |
Balance Sheet
The company has 2.45 billion in cash and 24.78 billion in debt, giving a net cash position of -22.33 billion or -47.96 per share.
| Cash & Cash Equivalents | 2.45B |
| Total Debt | 24.78B |
| Net Cash | -22.33B |
| Net Cash Per Share | -47.96 |
| Equity (Book Value) | 80.14B |
| Book Value Per Share | 172.12 |
| Working Capital | 6.57B |
Cash Flow
In the last 12 months, operating cash flow was 6.85 billion and capital expenditures -2.40 billion, giving a free cash flow of 4.45 billion.
| Operating Cash Flow | 6.85B |
| Capital Expenditures | -2.40B |
| Free Cash Flow | 4.45B |
| FCF Per Share | 9.57 |
Margins
Gross margin is 57.72%, with operating and profit margins of 27.21% and 13.78%.
| Gross Margin | 57.72% |
| Operating Margin | 27.21% |
| Pretax Margin | 18.21% |
| Profit Margin | 13.78% |
| EBITDA Margin | 33.82% |
| EBIT Margin | 27.21% |
| FCF Margin | 14.57% |
Dividends & Yields
This stock pays an annual dividend of 6.19, which amounts to a dividend yield of 1.53%.
| Dividend Per Share | 6.19 |
| Dividend Yield | 1.53% |
| Dividend Growth (YoY) | 61.25% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 68.57% |
| Buyback Yield | 22.70% |
| Shareholder Yield | 24.22% |
| Earnings Yield | 2.23% |
| FCF Yield | 2.36% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 28, 2011. It was a forward split with a ratio of 5.
| Last Split Date | Nov 28, 2011 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
Novozymes has an Altman Z-Score of 4.33 and a Piotroski F-Score of 6.
| Altman Z-Score | 4.33 |
| Piotroski F-Score | 6 |